InNexus Biotechnology collaborates with the NCI

InNexus Biotechnology has announced that it has entered into a collaboration agreement with the National Cancer Institute to research antibody-based technologies developed by InNexus. InNexus has collaborations with XERIS Pharmaceuticals, Genhelix, Cephalon, Affimed and GlaxoSmithKline

InNexus Biotechnology and Xeris Pharmaceuticals enter partnership

On December 12 2009 InNexus Biotechnology Inc and Xeris Pharmaceuticals Inc entered a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus’ Dynamic Cross Linking (DXL) antibodies using Xeris’ proprietary formulation-injection technologies.